Table 3.
con (Ct value) | con | 7 days | 14 days | 21 days | 28 days | 35 days | +anti-IL-17 antibody | |
---|---|---|---|---|---|---|---|---|
T cell-related | ||||||||
IL-17 | 37·02 | 1·00 | 2·62 | 1573·6 | 15·05 | 49·24 | 80·54 | 5·36 |
IL-17F | 35·65 | 1·00 | 0·99 | 32·22 | 0·89 | 1·49 | 1·47 | 0·22 |
IL-6 | 32·75 | 1·00 | 1·62 | 33·01 | 3·30 | 2·86 | 6·92 | 2·52 |
IFN-γ | 36·92 | 1·00 | 1·47 | 870·08 | 20·07 | 45·46 | 63·41 | 38·14 |
TNF-α | 30·68 | 1·00 | 1·27 | 58·08 | 3·26 | 4·65 | 12·10 | 0·34 |
ROR-γt | 26·37 | 1·00 | 1·10 | 6·02 | 0·70 | 0·92 | 3·09 | 0·43 |
T-bet | 28·82 | 1·00 | 1·04 | 9·03 | 0·88 | 1·35 | 3·66 | 1·05 |
GATA-3 | 27·13 | 1·00 | 1·17 | 5·64 | 0·14 | 0·77 | 2·46 | 0·36 |
FoxP3 | 30·11 | 1·00 | 0·86 | 10·59 | 0·84 | 1·59 | 4·63 | 0·39 |
Neurotrophic factor | ||||||||
NGF | 30·35 | 1·00 | 0·96 | 1·13 | 1·00 | 3·00 | 2·91 | 0·10 |
CNTF | 23·64 | 1·00 | 0·92 | 3·96 | 3·49 | 4·15 | 7·07 | 2·53 |
Thy1 | 19·48 | 1·00 | 0·90 | 0·93 | 0·65 | 0·78 | 1·51 | 0·58 |
Gap3 | 21·93 | 1·00 | 0·92 | 1·04 | 0·76 | 0·80 | 1·99 | 0·87 |
Rho | 12·47 | 1·00 | 0·89 | 0·18 | 0·49 | 1·04 | 1·13 | 0·05 |
Crx | 17·93 | 1·00 | 0·85 | 0·24 | 0·75 | 1·19 | 1·31 | 0·17 |
con*: tissue counterparts were obtained from the control Lewis rats. The relative expression of the genes of interest was measured by quantitative reverse transcription–polymerase chain reaction (qRT–PCR), the same method with the EAU rats, and set as 1·00. Genes expression at least a 2-fold change was recognized as being significantly altered and in bold type. IL: interleukin; IFN: interferon; TNF: tumour necrosis factor; ROR-γt: retinoic acid receptor-related orphan receptor gammat; GATA-3: GATA-binding protein 3; FoxP3: forkhead box protein 3; TGF: transforming growth factor; NGF: nerve growth factor; CNTF: ciliary neurotrophic factor.